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The burden of epidermal growth factor receptor (EGFR) exon 20 insertion mutation (Exon
20ins) in non-small cell lung cancer is not well understood. A systematic review was con-
ducted to identify evidence on mutation frequency, prognostic impact, clinical, patient-
reported, and economic outcomes associated with Exon 20ins.
Materials andmethods
Searches were conducted in Embase and Medline and supplemented with recent confer-
ence proceedings. Included studies were not limited by intervention, geography, or publica-
tion year.
Results
Seventy-eight unique studies were included; 53 reporting mutation frequency, 13 prognostic
impact, 36 clinical outcomes, and one humanistic burden. No economic burden data were
identified. The frequency of Exon 20ins mutation ranged from 0.1% to 4% of all NSCLC
cases and 1% to 12% of all EGFRmutations. Data on the prognostic impact of Exon 20ins
were heterogeneous but highlighted poorer outcomes in patients with Exon 20ins mutation
compared with patients with other EGFRmutations and EGFR wildtype across a wide range
of therapies and treatment lines. Comparative evidence on the clinical efficacy and safety of
currently available therapies were limited, as were sample sizes of studies reporting on real-
world effectiveness. Nine single-arm trials and 27 observational studies reported clinical out-
comes for patients with Exon 20ins. Trends towards better survival and response were
observed for chemotherapy compared with TKIs as first-line treatments. For subsequent
treatment lines, novel targeted therapies provided encouraging preliminary responses while
results for chemotherapy were less favorable. Limited safety data were reported. One con-
ference abstract described the symptom burden for Exon 20ins patients with fatigue and
pain being most common.
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Conclusion
Findings of the systematic review show a high unmet need for safe and efficacious treat-
ments for patients with Exon 20ins as well and need for further evidence generation to better
understand the patient-level and economic impact for these patients.
Introduction
Approximately 30% of non-small cell lung cancer (NSCLC) tumors harbor a mutation in the epi-
dermal growth factor receptor (EGFR) gene, with geographical variation in rates reported to be
highest in Asia (38%) and lowest in Europe (14%) [1]. Approximately 85%-90% of EGFRmuta-
tions comprise Exon 19 deletion and L858R point mutations of Exon 21 (classical EGFRmuta-
tions) [2, 3], while the remaining 10%-15% comprise uncommon mutations, including Exon 20
insertion (Exon 20ins) mutation (4–12%), L861Q (3%), G719X (2%) and S768I (1%) [4, 5]. The
Exon 20ins mutation is the third most common type of EGFRmutation in NSCLC, after Exon 19
deletions and Exon 21 L858R point mutations [2, 4, 5]. The expanded use of next-generation
sequencing (NGS) in clinical practice, and thus an improved ability to identify rare variants, has
led to an increase in the incidence of uncommon EGFRmutations, including Exon 20ins [6]. The
growing incidence and high heterogeneity (with potentially variable sensitivity to EGFR blockage)
of Exon 20ins mean this uncommon mutation is increasingly clinically relevant [6, 7].
The population of patients with NSCLC and Exon 20ins is not well recognized, and no specific
treatment recommendations have been made in European (European Society for Medical Oncol-
ogy [8]) or US (National Comprehensive Cancer Network [9]) clinical guidelines [8, 9]. Patients
are usually treated with chemotherapy or EGFR tyrosine kinase inhibitors (TKIs) [10], although,
EGFR Exon 20 mutations (including Exon 20ins) have been associated with resistance/insensitiv-
ity to currently available TKIs [3–5, 11]. The US FDA recently granted Breakthrough Therapy
Designations for two investigational targeted therapies (amivantamab [JNJ-372] [12] and mobo-
certinib [TAK-788] [13]) for the treatment of patients with metastatic NSCLC with EGFR Exon
20ins mutation whose disease has progressed on or after platinum-based chemotherapy. Even as
the treatment landscape for NSCLC Exon 20ins rapidly evolves, clinical outcomes and the opti-
mal treatment choice remain poorly understood for this patient population.
Global variations in the frequency of mutation and prognostic impact of Exon 20ins, as well
as the humanistic and economic burden for this specific population, are also not well under-
stood or reported. Thus, a systematic literature review (SLR) was conducted to provide a com-
prehensive summary of the available evidence on the burden of Exon 20ins in NSCLC.
Evidence was collated on: 1) the global frequency of Exon 20ins, 2) the prognostic impact of
Exon 20ins compared to other EGFRmutations and the association between other patient fac-
tors and Exon 20ins, 3) treatment patterns and clinical outcomes in patients with Exon 20ins,
and 4) the cost, resource use, and humanistic burden of Exon 20ins. Findings from the SLR
will help to consolidate the current body of evidence and identify gaps for future research.
Methods
The SLR was conducted using rigorous methodology and in accordance with the Cochrane
Handbook for Systematic Reviews of Interventions [14] and the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guidelines [15] with regards to the methods
used to search, identify, review, and summarize the available evidence.
PLOS ONE SLR on the burden of EGFR Exon 20 insertion mutation
PLOSONE | https://doi.org/10.1371/journal.pone.0247620 March 8, 2021 2 / 20
interests: HB, HE, and NS are paid employees of
Evidera, a consultancy which provides consulting
and other research services to pharmaceutical,
medical device, and other organizations. In their
salaried positions, they work with a variety of
companies and are precluded from receiving
payment or honoraria directly from these
organizations for services rendered. Evidera
received funding from Janssen for the involvement
of their employees in this research. TL and PM are
paid employees of Janssen. This does not alter our
adherence to PLOS ONE policies on sharing data
and materials. There are no patents, products in
development or marketed products associated with
this research to declare. CC has no conflicts to
disclose.
Identification and selection of studies
The database searches were conducted in MEDLINE and Embase via Ovid on September 10,
2019 and were not limited by intervention, study design, geography, or publication year. The
search strategy is presented in S1 Table. In addition to the databases 2019 and 2020 proceed-
ings from ESMO, World Conference on Lung Cancer (WCLC), and American Society of Clin-
ical Oncology (ASCO) conferences were searched. Bibliographies of published systematic
reviews and/or meta-analyses of relevant studies that were identified during the database
searches were also reviewed to identify additional, relevant publications.
Pre-defined inclusion and exclusion criteria were used to evaluate the titles and abstracts of
the records identified by the searches in the first level of review. Full-text articles of abstracts
that were deemed relevant during the first level of review were retrieved and reviewed. Title
and abstract screening were conducted by a single researcher, while full-text screening was
conducted by two independent researchers with disagreements resolved by a third researcher.
The pre-defined selection criteria based on the populations, interventions and comparators,
outcomes and study design (PICOS) framework are shown in Table 1.
Data extraction
Standardized data extraction tables developed in Microsoft Excel1 were used to capture and
present key evidence from each of the studies that met the pre-defined inclusion and exclusion
criteria. Data for all topics were extracted by one independent researcher and validated by a
second researcher to ensure their accuracy.
Table 1. PICOS selection criteria.
Selection Criteria




Outcomes Epidemiology: Incidence, prevalence, and frequency of mutation (by subtype, race, age,
or other patient subgroups)
Prognostic value of Exon 20ins mutation in terms of OS, PFS, and ORR
Clinical burden: Efficacy (OS, PFS, ORR) and safety
Humanistic burden: HRQoL, utilities, and symptoms
Economic burden: Cost (direct and indirect), resource use, and cost-effectiveness
outcomes
Study Design Epidemiological (population/registry-based)
Observational cohort studies (prospective or retrospective)
Cross-sectional studies
RCTs
Prospective, interventional studies (non-randomized trials)
Geography No limit
Language No limit
Sample size Excluded epidemiology studies wherein the number of NSCLC patients genotyped for
Exon 20 insertion were<250
Excluded prognostic impact and clinical burden studies wherein the number of Exon 20
insertion patients were<10
Abbreviations: EGFR = epidermal growth factor receptor; ins = insertion; NSCLC = non-small cell lung cancer;
ORR = objective response rate; OS = overall survival; PFS = progression-free survival; RCT = randomized controlled
trial; TKI = tyrosine kinase inhibitor
https://doi.org/10.1371/journal.pone.0247620.t001
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Results
Study selection
The electronic searches yielded 2,499 unique records for title and abstract screening (Fig 1).
A total of 386 records were screened at the full-text level, with most excluded citations
being conference abstracts that reported limited information (113/317). After applying the
PICOS criteria and conducting searches of conference abstracts, 78 articles were included: 53
reporting the frequency of Exon 20ins, 13 reporting on the prognostic impact, 36 reporting
clinical outcomes, and one reporting on the humanistic burden (S2 Table). No eligible articles
reported on the economic impact of Exon 20ins.
Frequency of mutation
Study characteristics. Studies reporting the frequency of the Exon 20ins mutation varied
with regards to population ethnicity or global region assessed, with most studies reporting
data from Asia Pacific (n = 22 studies), followed by Europe (n = 12), the US (n = 10), and Latin
America (n = 7). Most studies were single-center (n = 38), while 14 were multi-center and one
was a meta-analysis.
The most commonly reported mutation test methodology was real-time polymerase chain
reaction (RT-PCR)/Sanger (n = 16), followed by RT-PCR/Cobas (n = 6), Amplification Refrac-
tory Mutation System™ (ARMS; n = 6), NGS/capture-based comprehensive genomic profiling
(n = 4), and mass spectroscopy genotyping (n = 2). Twenty studies did not report the method-
ology used for mutation testing.
Frequency of mutation. Across countries, the frequency of EGFR Exon 20ins ranged
from 0.1%–4.0% of all NSCLC cases and from 1%–12% of all EGFRmutations (Table 2).
The highest frequencies were reported for the Asia Pacific region (0.1%–4.0% among all
NSCLC cases and 1%–5% of EGFRm tumors) and the US (0.5%–2.6% among all NSCLC cases
and 5%–12% of EGFRm tumors).
Ten studies reported patient-level factors that significantly impact the frequency of Exon
20ins [4, 5, 11, 16–22]. The mutation was found to be more common in women (47% of Exon
20ins vs. 28% of EGFR wildtype (WT), p = 0.003) [19], Asian patients (15% of Exon 20ins vs.
4% of EGFRWT, p = 0.02) [5], never-smokers (56% of Exon 20ins vs. 20% of EGFRWT,
p<0.0001 [5] and 67% of Exon 20ins vs. 26% of other uncommon EGFRmutations, p<0.01)
[20], older patients (p = 0.01, p = 0.032 vs. Exon 19 deletion/L858R [11, 19]), and those with
adenocarcinoma histology (100% for Exon 20ins vs. 76% of G719X, 82% of L861Q/P, 89% of
L858R, and 93% of Exon 19 deletion [p-values not reported]) [22].
Prognostic impact
Study characteristics. Studies that reported on the prognostic impact of Exon 20ins var-
ied significantly with regards to the genotypes compared, line and type of therapy received,
and patient ethnicity. The majority of studies were retrospective chart reviews (n = 10), with
three exceptions: one post-hoc analysis of trial data (LUX-Lung 2, LUX-Lung 3, and LUX--
Lung 6) [21] and two prospective registries [23, 24]. Most studies were conducted in Asia
(n = 8), with the remainder in the US (n = 3), Europe (n = 1), and Latin America (n = 1). Half
of the studies evaluated TKI-treated populations and half evaluated mixed-treatment popula-
tions (i.e. chemotherapy and/or TKIs). A majority evaluated populations receiving mixed lines
of therapy, although some specifically evaluated first-line (n = 3) and subsequent lines (n = 2)
of therapy.
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The genotypes most frequently assessed alongside Exon 20ins with regards to outcomes of
interest were classic mutations (Exon 19 deletion and L858R) and the T790Mmutation, evalu-
ated in nine and six studies, respectively. Other mutations assessed alongside Exon 20ins, such
as Exon 18 mutations, other uncommon mutations, and EGFR wildtype (wt) were not
reported frequently enough to draw conclusions across the literature.
Exon20ins vs. classic mutations. Nine studies demonstrated a survival and/or response
benefit for patients with classic EGFRmutations (Exon 19 deletion and L858R) compared with
Exon 20ins [11, 19, 20, 25–30]. OS in patients with the classic mutations was at least double
that of patients with Exon 20ins in nearly all studies comparing these groups [11, 20, 26, 30,
31]. Median OS ranged from 4.8–16.8 months in the Exon 20ins groups (range 11–84 patients)
and 17.3–31.6 months in the groups with classic mutations (range 186–1,816 patients)
(Table 3).
One exception was a retrospective study fromMemorial Sloan Kettering Cancer Center in
New York, which reported comparable median OS for Exon 20ins (46 patients) vs. classic
mutations (258 patients); 26 versus 31 months (p = 0.53) [11]. The majority of patients in this
study received chemotherapy followed by erlotinib, whereas most other studies evaluated
TKIs. In a retrospective case series from National Taiwan University, median OS in 43 patients
Fig 1. PRISMA diagram.
https://doi.org/10.1371/journal.pone.0247620.g001
Table 2. Global Exon 20ins rates.
Region Frequency of EGFR Exon 20ins (%)
# Studies NSCLC # Studies EGFRm Positive
US 9 0.5–2.6% 7 5–12%
Latin America 7 1.3–2.1% 5 5–8%
Europe 13 0.3–1.3% 10 4–12%
Asia Pacific 28 0.1–4.0% 16 1–5%
South Asia 5 0.3–3.4% 4 1–4%
South East Asia 4 0.1–2.4% 2 2–3%
Japan 4 1.8–2.4% 2 2–5%
China 9 0.3–2.9% 7 2–5%
Taiwan 3 1.3–4.0% 2 3–4%
Abbreviations: EGFRm = epidermal growth factor receptor mutation; Exon 20ins = exon 20 insertion mutation; NSCLC = non-small cell lung cancer
https://doi.org/10.1371/journal.pone.0247620.t002
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with Exon 20ins receiving first-line pemetrexed approached that of 1,064 patients with classic
EGFRmutations receiving first-line chemotherapy or TKIs; 28 months versus 31.6 months,
whereas 16 Exon 20ins patients treated with first-line TKI-containing regimens had much
lower survival (16.8 months) [32]. Most studies evaluated mixed lines of therapy, so the impact
across individual lines of therapy is unclear.
Notably, the presence of an Exon 20ins mutation alone appears to have poorer outcomes
than Exon 20ins with concomitant classic EGFRmutations (del 19 and L858R). A retrospective
case series conducted in in Latin America showed that Exon 20ins alone (88 patients) was asso-
ciated with significantly shorter survival compared to Exon 20ins with a concomitant classic
EGFRmutation (32 patients); 14.6 vs.17.3 months (p = 0.017) [33].
Table 3. Summary of prognostic impact of Exon20 insertions compared to other genotypes.
Range Median OS Range Median PFS Range ORR
(months) (months) (%)
TKIs
Exon 20ins 4.8–19 1.4–3.0 0–20%
6 studies 8 studies 7 studies
177 patients (range 11–67) 183 patients (range 11–
67)
194 patients (range 11–
67)
Classic EGFRm (del 19 or
L858R)
19.6–27.7 8.5–15.2 27.4–84%
3 studies 3 studies 5 studies
501 patients (range 37–278) 501 patients (range 37–
278)
1193 patients (range 37–
692)
T790M 13.5–27.7 1.0–2.9 0–25%
3 studies 3 studies 4 studies
67 patients (range 14–30) 67 patients (range 14–30) 114 patients (range 14–
47)
Wild-type 10.4–21 2 16.50%
2 studies 1 study 1 study
990 patients (range 20–88) 1261 patients (range 15–
39)
1261 patients (range 20–
102)
TKI and/or Chemotherapy
Exon 20ins 14.6–26 4.8–6.0 5.1–28%
4 studies 2 studies 2 studies
233 patients (range 258–
1,816)
99 patients (range 15–39) 172 patients (range 20–
102)
Classic EGFRm (del 19 or
L858R)
17.3–31.6 No study 0 studies
3 studies
2106 patients
T790M 12.3 8.2 0 studies
1 study 1 study
9 patients 9 patients
Wild-type 0 studies 0 studies 0 studies
Abbreviations: del = deletion; EGFR = epidermal growth factor receptor; ins = insertion; LOT = line of therapy;
m = mutation; ORR = objective response rate; OS = overall survival; PFS = progression-free survival; TKI = tyrosine
kinase inhibitor; WT = wild type
�Data is for a subtype of Exon 20ins patients with a specific insertion (V769_D770insASV (2307–2308)
GCCAGCGTG)
https://doi.org/10.1371/journal.pone.0247620.t003
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The impact of Exon 20ins compared to classic EGFRmutations is even more pronounced
for PFS, with median PFS 4.2 to 6.0 times longer in patients with classic mutations (range: 1.4–
3.0 months [range 11–67 patients] vs. 8.5–15.2 months [range 37–278 patients]) [20, 26, 27].
Similarly, the included studies found a higher response rate for classic EGFRmutations com-
pared to Exon 20ins. Studies examining PFS and objective response rate (ORR) evaluated
TKIs across mixed lines of therapy, and therefore the relationship in the context of treatment
and line of therapy cannot be examined.
Exon 20ins vs. T790M. Four studies compared OS for patients with Exon 20ins vs.
T790M [21, 23, 27, 34], with most demonstrating a numerical but not statistically significant
improvement in OS for patients with the T790Mmutation. Studies wherein patients received
TKIs across mixed lines of therapies showed a survival benefit for patients with T790M (range
14–30 patients) compared to Exon 20ins (range 5–67 patients); 14.9–27.7 months vs. 9.2–12.5
months [21, 27]. In contrast, one study of TKIs given in subsequent lines of therapy showed
no difference in OS between Exon 20ins (29 patients) vs. T790M (23 patients); 12.9 vs. 13.5
months [23]. This study included patients evaluated from 2005 to 2014, prior to approval of
osimertinib. Therefore, it is possible that line of therapy may cause these differences.
One retrospective cohort study at a single center in India in patients receiving a combina-
tion of TKI and chemotherapy demonstrated longer median OS in patients with Exon 20ins
(15 patients) compared to those with T790M (9 patients); 15.8 months vs. 12.3 months [34].
Findings on PFS were similarly inconclusive for Exon 20ins compared to T790M, with
three studies showing longer PFS for patients with T790M and one showing shorter PFS.
Among the three studies reporting a longer PFS for T790M, the difference ranged from 0.2–
2.2 months (range 15–29 Exon 20ins patients and 9–23 T790M patients) [21, 23, 34], while the
fourth study in which patients received either erlotinib or gefitinib reported longer PFS for
patients with Exon 20ins (67 patients) vs. T790M (30 patients); 3.0 months vs 1.0 months [31].
Studies presented varied conclusions on ORR. Two studies [23, 25] reported marginally
higher response rates for the T790M patients compared with Exon 20ins patients; the first
study [23] reported lower response rates for T790M patients (23 patients) compared with
Exon 20ins patients (29 patients), and the second [25] observed no objective responses in
either group. No study evaluated statistical significance between these mutation groups for this
outcome, and therefore no conclusions could be drawn.
Exon 20ins vs. wildtype. Two studies [26, 35] compared outcomes for Exon 20ins (11 and
25 patients) versus EGFRWT (272 and 718 patients). In both studies, patients received erloti-
nib or gefitinib, with similar overall survival (OS) between groups (no statistically significant
differences). One study compared progression-free survival (PFS) for Exon 20ins (11 patients)
versus EGFRWT (272 patients), and found similar median PFS between groups;1.4 vs. 2.0
months, respectively [26]. Given the limited sample size of the Exon 20ins group compared to
WT group, these findings should be interpreted while considering this imbalance.
Clinical burden
Study characteristics. Similar to the studies reporting prognostic impact, studies that
reported clinical outcomes for patients with Exon 20ins varied significantly with regards to
study design, setting, line and type of therapy received, and sample size (Table 4).
No comparative studies were identified, but rather, nine single-arm phase I/II trials (range
11–115 patients) [40, 42, 43, 45–47, 49, 52, 53] two prospective cohort studies (29 and 35
patients) [23, 29, 39], two pooled analyses of clinical trials (21 and 23 patients) [21, 48], and 22
retrospective observational studies (range 15–165 patients). Half of the studies (n = 16)
reported on subgroups or select cohorts of patients with Exon 20ins from studies with broader
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study populations, and half were conducted in Asia (n = 14), followed by the US (n = 8). Most
studies evaluated populations receiving subsequent lines of therapy (n = 14), followed by
mixed lines (n = 13), and first-line treatment (n = 7). Two studies did not report the line of
therapy received [28, 35]. The included studies were broadly similar in terms of gender,
median age, and histology (most were adenocarcinomas), but varied with regards to perfor-
mance and smoking status.
First-line clinical outcomes. Nine studies reported the clinical effectiveness of various
first-line treatment regimens in patients with Exon 20ins [10, 21, 29, 32–34, 36–38]. Overall,
platinum- and pemetrexed-based chemotherapies were the most efficacious first-line treat-
ments for patients with Exon 20ins [10, 32, 33, 37]. Median OS ranged from 7.1–16.8 months
for TKIs (range 16–27 patients) [10, 32, 34] and 6.3–28 months for chemotherapy (range 10–
58 patients) [32]. One study, which included 88 patients receiving a mix of TKI (28.0%) and
platinum-based chemotherapy (72%), reported a median OS of 16.4 months [33]. Median PFS
and ORR were also more favorable for patients with Exon 20ins receiving chemotherapy
(median PFS: 3.4–6.9 months for chemotherapy-based regimens [range 10–105 patients] [29,
32, 33, 37, 38] vs. 1.8–6.4 months for TKIs [range 15–25 patients] [21, 32–34, 37]; ORR: 23%–
29% [29, 32, 38] for chemotherapy [range 24–45 patients] vs. 0%–8.7% [21, 32, 34] for TKIs
[range 15–43 patients]). None of the studies reported safety outcomes for patients with Exon
20ins.
Second- or later-line clinical outcomes. Sixteen studies (reported across 21 publications)
reported the clinical efficacy/effectiveness and safety of various subsequent-line treatment regi-
mens in patients with Exon 20ins, but based on very limited sample sizes (range 11–165
patients) [10, 23, 24, 29, 30, 37, 39–44, 45–53].
Two studies reported median OS for patients receiving TKIs in subsequent lines of therapy
(29 and 18 patients) [10, 23], ranging from 12.9–15.3 months; one of the studies also reported
OS for 17 patients receiving chemotherapy (17.1 months) and 21 patients receiving immuno-
therapy (8.0 months) [10]. One single-arm phase two trial of an investigational compound,
luminespib, reported a median OS of 12.8 months, although this trial included only 29 patients
with Exon 20ins [47].
Median PFS ranged from 4.1–4.8 months among patients receiving subsequent chemother-
apy (range 12–34 patients) [54, 56] and 1.9–3.7 months among those receiving subsequent
TKIs (range 15–29 patients) [23, 37, 42, 44], with a recent single-arm trial of high-dose osimer-
tinib (160 mg) conducted in 21 patients reporting a median PFS of 9.6 months [43]. PD-1/L1
inhibitors (21 patients) and luminespib (29 patients) were both associated with a median PFS
of 3.3 months, across two separate studies [29, 47]. In two ongoing single-arm trials, amivanta-
mab showed a median PFS of 8.3 months among 39 patients [51], while the mobocertinib trial
reported median PFS of 7.3 months in 28 patients [30].
ORRs for amivantamab [51], mobocertinib [30], and CLN-081 [53] were 41%, 43%, and
35%, respectively. For poziotinib, a single-center, single arm trial conducted in 44 patients
fromMD Anderson, reported an ORR of 43% [45], while a larger multicenter single-arm trial
(ZENITH20-1) conducted in 115 patients reported a much lower ORR of 14.8% [46]. ORRs
for TKIs and chemotherapies varied significantly across the included studies, ranging from
0%–20% and 17%–42%, respectively.
Safety outcomes were reported for the second-line trials for luminespib [48], osimertinib
[42, 46], amivantamab [51], mobocertinib [30, 40], CLN-081 [53], and poziotinib [46]. The
most commonly reported treatment-related adverse events (TRAEs) for luminespib (29
patients) were diarrhea (83%) and ocular toxicity (76%), while hypertension (10%) and hypo-
phosphatemia (7%) were the most frequently reported grade 3+ AEs [47]. For mobocertinib
(28 patients), diarrhea (85%) and rash (43%) were the most common TRAEs and diarrhea
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(26%), hypokalemia, nausea, and stomatitis (7% each) were the most common grade 3
+ adverse events (AEs) [30]. Similarly, results from ZENITH20-1 (115 patients) show the most
common grade 3 TRAEs associated with poziotinib to be diarrhea (25%), rash (28%), and sto-
matitis (9%) [46]. CLN-081 (22 patients) was associated with rash (60%), stomatitis (13%), and
dry skin (13%), with no serious or grade 3 AEs or AEs leading to discontinuations reported
[53]. CHRYSALIS (50 patients), showed amivantamab to be associated with grade 3+ TRAEs
in 6% of patients with Exon 20ins, with only one grade 3+ case of diarrhea and no grade 3
+ rash reported [51]. Dose reductions were reported for 21%, 25%, 0%, and 4% of patients in
the luminespib [47], mobocertinib [40], CLN-021 [53], and amivantamab [49] trials respec-
tively. The Korean Cancer Study Group osimertinib trial reported the most frequent AEs to be
nausea and vomiting; 20% each.
Mixed-line clinical outcomes. Across the studies reporting on mixed lines of therapies,
there was a trend towards greater OS benefit with chemotherapy regimens (26–29.4 months)
compared with TKI regimens (4.8–19 months). Only one study reported a median PFS of 4.5
months based on 22 patients, compared to a range of 1.4–3.1 months for TKIs (range 11–67
patients).
None of the mixed-line studies reported safety outcomes.
Humanistic and economic burden
One study assessed the symptoms and health-related quality of life (HRQoL) impact associated
with Exon 20ins mutation by conducting interviews with clinical experts (n = 5) and patients
with NSCLC (n = 9/10 with Exon 20ins). Symptoms reported by the clinical experts included
shortness of breath, chest pain, bone/other pain, and substantial emotional impacts. The study
found that causes of poor HRQoL were frequent disease-related symptoms such as fatigue
(90% of patients), pain (70%), shortness of breath (70%), and cough (60%), as well as negative
impacts on daily activities including household chores and self-care (60%), social activities
(50%), work (50%), and family life (40%).
The SLR did not identify any published economic data on cost or resource use associated
with Exon 20ins.
Discussion
The aim of this SLR was to identify and comprehensively summarize the available evidence on
the epidemiologic, clinical, humanistic, and economic burden of the EGFR Exon 20ins muta-
tion in adult patients with advanced/metastatic NSCLC. Screening approximately 2,500 unique
citations yielded 78 articles meeting the prespecified inclusion criteria, the majority of which
reported on frequency of mutation (n = 53), clinical outcomes (n = 36), and prognostic impact
(n = 13). Only one abstract reporting the humanistic burden of Exon 20ins was identified, and
no eligible economic studies were available. To our knowledge, this SLR provides the most
comprehensive assessment of the literature reporting on the burden of the Exon 20ins muta-
tion. Methods to quantitatively synthesize the available evidence via meta-analysis were con-
sidered, but differences across the included studies with regards to geography, study design,
test methodology, and included patient populations were expected to impact the validity and
certainty of findings.
The frequency of the Exon 20ins mutation ranged from 0.1%–4.0% among all patients with
NSCLC and 1%–12% among those with EGFRmutations. Most publications reporting on fre-
quency of mutation were based on Asian or US-based single-center studies, with substantial
variation in the genotyping method used. More than eighty unique EGFR Exon 20ins muta-
tions have been identified, but only comprehensive testing methods, such as next generation
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sequencing have the ability to detect all known and unknown variants. Unfortunately, many of
the included studies did not report the method used for EGFR Exon 20ins detection or used
PCR-based testing that focused only on the most common mutations. Therefore, the frequency
of EGFR Exon 20ins may have been significantly underestimated. Limited findings were also
reported on patient-level factors that impact the frequency of Exon 20ins (i.e., age, smoking
status, gender). Further research aimed at better understanding the frequency of other molecu-
lar characteristics and co-occurring mutations in patients with Exon 20ins is needed. However,
current evidence suggests that EGFR Exon 20ins tend to be mutually exclusive with other com-
mon NSCLC mutation types including other EGFRmutations and mutations in KRAS, BRAF,
HER2, NRAS, PIK3CA,MAP2K1/MEK1, AKT, as well as ALK rearrangements [4, 57, 58].
Findings from the SLR also indicated that patients with advanced NSCLC and the Exon 20ins
mutation have poorer treatment outcomes compared with patients with other EGFRmutations
and EGFRWT across different therapy options and treatment lines. Patients with Exon 20ins
treated with afatinib had the lowest PFS, and OS compared to other uncommon EGFRmuta-
tions in the first-line setting and the lowest ORR compared to other common/uncommon
EGFRmutations in the second-line setting. Treatment with TKIs was generally associated with
worse outcomes in patients with Exon 20ins compared with other mutations across treatment
lines; this included lower PFS than those with Exon 18 and T790Mmutations in the first-line
setting and lower PFS and OS than those with two other types of Exon 20 mutations in the sec-
ond-line setting. Patients with Exon 20ins who were treated with chemotherapy had signifi-
cantly shorter OS and comparable PFS to patients with EGFRWT in the first-line setting. The
clinical differences between T790M and Exon 20ins mutations in NSCLC were less clear than
with the classic EGFRmutations.
There was a limited number of comparative studies investigating the efficacy and safety of
currently available therapies for patients with Exon 20ins. In the first-line setting, there was a
trend towards longer OS and PFS and a higher ORR with chemotherapy regimens compared
with TKI regimens. A recent large cohort study of patients with advanced NSCLC with Exo-
n20ins (n = 119) suggested that first-line pemetrexed-based chemotherapy regimens are asso-
ciated with longer OS and PFS than non-pemetrexed-based chemotherapy in this population
[59]. While chemotherapy appeared to be associated with longer OS and lower ORR than
TKIs in second- and later-line settings in this SLR, there was no clear trend towards greater
PFS benefit with either type of therapy. Recently, an indirect treatment comparison that uti-
lized propensity score modeling to match real-world data from the US Flatiron database to
patients in the ongoing phase 1–2 mobocertinib trial [30] showed a significant improvement
for mobocertinib compared to current standard of care (median PFS: 7.3 vs. 3.5 months, HR:
0.44 [95% CI 0.22, 0.91]) [60]. The real-world evidence from this study also highlighted a lack
of standard of care for subsequent-line treatment of patients with Exon 20ins; reporting a mix
of immune-oncologic agents (IOs), TKIs, and chemotherapy [60]. Results from our review
showed limited data on the effectiveness and/or safety of IOs in patients with Exon 20ins, how-
ever, ongoing research will further assess the impact of PD-1/PD-L1 blockade in these patients,
given recent findings that patients with EGFR Exon 20ins had increased PD-L1 expression and
improved outcomes compared to those withHER2 Exon 20ins [61]. In addition, several
emerging compounds, such as DS-2087b [62] and BLU-945 [63], have demonstrated anti-
tumour activity in preclinical studies. It should be noted that most studies identified in this
SLR included a small number of patients with Exon 20ins, and there was considerable hetero-
geneity in the clinical and demographic characteristics of the enrolled patients. Further,
included studies differed in their methodology, with only a small number of prospective stud-
ies identified.
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Despite these limitations, this review clearly highlights the gaps in the literature for the
humanistic and economic impact of the Exon 20ins mutation. Preliminary evidence suggests
that patients with Exon 20ins experience poor HRQoL and a substantial symptom burden, but
there remains a significant gap in our understanding of the humanistic and economic burden
on this patient population with a demonstrably poor prognosis.
Conclusions
Findings of this SLR illustrate a wide range in the frequency of Exon 20ins and highlight the
need for a better understanding of mutation drivers, including the impact of various test meth-
odologies. Results in terms of prognostic impact and clinical burden, while mainly based on
studies with a low sample size, indicated a high unmet need for novel efficacious therapies for
patients with advanced NSCLC and EGFR Exon 20ins. These patients have poorer treatment
outcomes compared with patients with other EGFRm and EGFR wild-type across different
currently available therapy options and treatment lines. While recent data on clinical outcomes
for EGFR Exon 20ins-targeting therapies are encouraging, evidence regarding their compara-
tive efficacy and safety versus established therapies (i.e. TKIs and chemotherapies) that are
known to be associated with poor outcomes are limited. The SLR also uncovered significant
gaps in the evidence with regards to data on the economic and humanistic burden of Exon 20
insertion, highlighting a substantial need for additional evidence generation to better under-
stand this among patients with Exon 20ins-positive NSCLC.
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